SCHEMBL4331124

SCHEMBL4331124

CSNC(=O)N/N=C/c1ccc(-c2cccc(C(F)(F)F)c2)o1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.72
ALDH1A1 P00352 4/20 0.72
MAPT P10636 6/20 0.64
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
HPGD P15428 3/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
HTT P42858 2/20 0.64
NPSR1 Q6W5P4 1/20 0.64
LMNA P02545 2/20 0.63
NPC1 O15118 2/20 0.62
POLB P06746 1/20 0.62
PKM P14618 2/20 0.48
RAB9A P51151 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
SLC9A1 P19634 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343474 0.89 KDM4E (0.68) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL4459309 0.83 KEAP1 (0.61) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL13496986 0.80 KDM4E (0.85) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL13611593 0.80 KDM4E (0.69) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL4331131 0.80 KDM4E (0.69) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL3490822 0.79 KDM4E (0.79) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL30460578 0.79 KDM4E (0.79) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL3490823 0.79 KDM4E (0.79) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL13497037 0.78 KDM4E (0.75) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL4453436 0.78 HPGD (0.70) KDM4EALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KDM4E 3010/4885ALDH1A1 1459/4885MAPT 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.